Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment

This is an open-label, multicenter, Phase 1 study to establish the safety and efficacy/tolerability of a single dose of 186RNL by the intraventricular route (via intraventricular catheter) for recurrence glioma in patients who received a prior treatment of 186RNL.

Trial Details

NCT ID
NCT05460507
Phase
PHASE1
Sponsor
Plus Therapeutics
Status
RECRUITING
Cancer Type
Glioblastoma (GBM) Brain Cancer
Interventions
  • Retreatment Rhenium Liposome
Locations (sample)
  • San Antonio, Texas, United States|29.42412,-98.49363

Key Eligibility Criteria

  • At least 18 years of age at time of screening.
  • Ability to understand the purposes and risks of the study and has signed a written informed consent document approved by the site-specific IRB.
  • Patient must present with biopsy and histology proven glioma following initial treatment with 186RNL. The type and grade of glioma to follow the 20…
  • At least 90 days from prior dose of 186RNL at time of screening.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Glioblastoma (GBM) Brain Cancer Trials on Trialify →